Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2025 | The importance of community physicians understanding the side effects of CAR T-cells and bispecifics

Gloria Iacoboni • 4 Sep 2025
SOHO 2025
General Antibodies CAR-T

Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the importance of community physicians understanding the potential toxicities associated with CAR T-cell therapy and bispecific antibodies, highlighting the need to be familiar with cytokine release syndrome (CRS), neurologic toxicities, cytopenias, and infections. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gloria Iacoboni

Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
25:30
Dual-targeting CARs in LBCL: trial updates and discussing the role of bridging therapy
Akil Merchant et al. • 26 Apr 2026
The potential of dual-targeting CAR-T approaches in R/R LBCL
1:18
The potential of dual-targeting CAR-T approaches in R/R LBCL
Gloria Iacoboni • 20 Feb 2026
Zamtocabtagene autoleucel, a tandem CD20-CD19 CAR, in R/R LBCL: data from the DALY 2-EU study
3:33
Zamtocabtagene autoleucel, a tandem CD20-CD19 CAR, in R/R LBCL: data from the DALY 2-EU study
Gloria Iacoboni • 20 Feb 2026
Using real-world evidence to shape CAR-T care in R/R DLBCL
3:34
Using real-world evidence to shape CAR-T care in R/R DLBCL
Gloria Iacoboni • 20 Feb 2026

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals